Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Occurrence, Concentrations, and Risks of Pharmaceutical Compounds in Private Wells in Central Pennsylvania.

Kibuye FA, Gall HE, Elkin KR, Swistock B, Veith TL, Watson JE, Elliott HA.

J Environ Qual. 2019 Jul;48(4):1057-1066. doi: 10.2134/jeq2018.08.0301.

PMID:
31589682
2.

Fate of pharmaceuticals in a spray-irrigation system: From wastewater to groundwater.

Kibuye FA, Gall HE, Elkin KR, Ayers B, Veith TL, Miller M, Jacob S, Hayden KR, Watson JE, Elliott HA.

Sci Total Environ. 2019 Mar 1;654:197-208. doi: 10.1016/j.scitotenv.2018.10.442. Epub 2018 Nov 6.

3.

Continuous Hydrologic and Water Quality Monitoring of Vernal Ponds.

Mina O, Gall HE, Chandler JW, Harper J, Taylor M.

J Vis Exp. 2017 Nov 13;(129). doi: 10.3791/56466.

4.

Estrogen Transport in Surface Runoff from Agricultural Fields Treated with Two Application Methods of Dairy Manure.

Mina O, Gall HE, Saporito LS, Kleinman PJ.

J Environ Qual. 2016 Nov;45(6):2007-2015. doi: 10.2134/jeq2016.05.0173.

PMID:
27898780
5.

Comparison of export dynamics of nutrients and animal-borne estrogens from a tile-drained Midwestern agroecosystem.

Gall HE, Sassman SA, Jenkinson B, Lee LS, Jafvert CT.

Water Res. 2015 Apr 1;72:162-73. doi: 10.1016/j.watres.2014.08.041. Epub 2014 Sep 6.

PMID:
25241950
6.

Implications of hydrologic connectivity between hillslopes and riparian zones on streamflow composition.

von Freyberg J, Radny D, Gall HE, Schirmer M.

J Contam Hydrol. 2014 Nov 15;169:62-74. doi: 10.1016/j.jconhyd.2014.07.005. Epub 2014 Jul 25.

PMID:
25106837
7.

Assessing impacts of land-applied manure from concentrated animal feeding operations on fish populations and communities.

Leet JK, Lee LS, Gall HE, Goforth RR, Sassman S, Gordon DA, Lazorchak JM, Smith ME, Jafvert CT, Sepúlveda MS.

Environ Sci Technol. 2012 Dec 18;46(24):13440-7. doi: 10.1021/es302599t. Epub 2012 Dec 4. Erratum in: Environ Sci Technol. 2013 Mar 5;47(5):2431. Javfert, Chad T [corrected to Jafvert, Chad T].

PMID:
23171355
8.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
9.

Hormone discharges from a midwest tile-drained agroecosystem receiving animal wastes.

Gall HE, Sassman SA, Lee LS, Jafvert CT.

Environ Sci Technol. 2011 Oct 15;45(20):8755-64. doi: 10.1021/es2011435. Epub 2011 Sep 19.

PMID:
21877728
10.

A review of studies on androgen and estrogen exposure in fish early life stages: effects on gene and hormonal control of sexual differentiation.

Leet JK, Gall HE, Sepúlveda MS.

J Appl Toxicol. 2011 Jul;31(5):379-98. doi: 10.1002/jat.1682. Epub 2011 May 10. Review.

PMID:
21557264
11.

Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G.

Clin Cancer Res. 2006 Mar 15;12(6):1760-7.

12.

A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.

Baars A, Claessen AM, Wagstaff J, Giaccone G, Scheper RJ, Meijer S, Schakel MJ, Gall HE, Meijer CJ, Vermorken JB, Pinedo HM, van den Eertwegh AJ.

Br J Cancer. 2002 Apr 22;86(8):1230-4.

13.

Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.

Baars A, Claessen AM, van den Eertwegh AJ, Gall HE, Stam AG, Meijer S, Giaccone G, Meijer CJ, Scheper RJ, Wagstaff J, Vermorken JB, Pinedo HM.

Ann Oncol. 2000 Aug;11(8):965-70.

PMID:
11038032
14.
15.

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.

Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM.

Lancet. 1999 Jan 30;353(9150):345-50.

PMID:
9950438
16.

Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.

Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ.

Clin Cancer Res. 1998 Feb;4(2):331-6.

17.

Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.

Korst AE, Gall HE, Vermorken JB, van der Vijgh WJ.

Cancer Chemother Pharmacol. 1996;39(1-2):162-6.

PMID:
8995515
18.

Safe handling of antineoplastic drugs. Results of a survey.

Nieweg RM, de Boer M, Dubbleman RC, Gall HE, Hesselman GM, Lenssen PC, van Maanen LW, Majoor PW, Ouwerkerk J, Slegt JH.

Cancer Nurs. 1994 Dec;17(6):501-11. Review.

PMID:
7820828
19.

A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg with 500 mg methylprednisolone succinate (Solu-Medrol) as a single intravenous dose in patients treated with noncisplatin chemotherapy.

Pieters RC, Vermorken JB, Gall HE, Nauta JJ, van Loenen AC, van Groeningen CJ, van Rijswijk RE, Brenninkmeijer JH, Pinedo HM.

Oncology. 1993 Jul-Aug;50(4):316-22.

PMID:
8497383
20.

Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.

van Groeningen CJ, Gall HE, Simons KA, van Loenen AC, Knobf MK, Nauta J, Vermorken JB, Pinedo HM.

Neth J Med. 1989 Dec;35(5-6):283-94.

PMID:
2699653
21.

[Phase I studies as non-therapeutic trials in oncology].

Brinkman-Woltjer LF, Vermorken JB, van Groeningen CJ, Gall HE, Pinedo HM.

Ned Tijdschr Geneeskd. 1988 Dec 17;132(51):2321-5. Dutch. No abstract available.

PMID:
3216917
22.

Development of a consultancy service in The Netherlands.

Poelhuis EH, Simonetti GP, Dubbelman AC, Donner GW, Gall HE.

Cancer Nurs. 1988 Dec;11(6):348-51. No abstract available.

PMID:
3233586
23.

Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.

van der Vijgh WJ, Elferink F, Vermorken JB, ten Bokkel Huinink WW, Klein I, Gall HE, Simonetti G, McVie JG, Pinedo HM.

Eur J Cancer Clin Oncol. 1988 Apr;24(4):621-7.

PMID:
3383966
24.

Pharmacokinetics of carboplatin after i.v. administration.

Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE, Pinedo HM.

Cancer Treat Rep. 1987 Dec;71(12):1231-7.

PMID:
3319135
25.

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.

Elferink F, van der Vijgh WJ, ten Bokkel Huinink WW, Vermorken JB, Klein I, Winograd B, Knobf MK, Simonetti G, Gall HE, McVie JG, et al.

Br J Cancer. 1987 Oct;56(4):479-83.

26.

[The Amsterdam Integrated Cancer Center and the nurses cooperate in nursing discussion and counseling services].

Poelhuis EH, Simonetti GP, Dubbelman AC, Gall HE.

Tijdschr Ziekenverpl. 1987 Jul 28;41(15):463-7. Dutch. No abstract available.

PMID:
3650982
27.

Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.

van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM.

Cancer Res. 1986 Sep;46(9):4831-6.

28.

Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.

Winograd B, Vermorken JB, ten Bokkel Huinink WW, Simonetti G, Gall HE, Knobf MK, van der Vijgh WJ, McVie JG, Pinedo HM.

Cancer Res. 1986 Apr;46(4 Pt 2):2148-51.

29.

Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin.

Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, Pinedo HM.

Clin Pharmacol Ther. 1986 Feb;39(2):136-44.

PMID:
3943271
30.

Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol).

Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, Splinter TA, Hart AA, Pinedo HM.

Ther Drug Monit. 1986;8(3):264-8.

PMID:
3750367
31.

Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

Vermorken JB, van der Vijgh WJ, Klein I, Hart AA, Gall HE, Pinedo HM.

Cancer Treat Rep. 1984 Mar;68(3):505-13.

PMID:
6538459
32.

Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.

Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, Pinedo HM.

Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74.

PMID:
6891650

Supplemental Content

Support Center